BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32797158)

  • 1. Exposing the High Heterogeneity of Circulating Pro B-Type Natriuretic Peptide Fragments in Healthy Individuals and Heart Failure Patients.
    Amplatz B; Sarg B; Faserl K; Hammerer-Lercher A; Mair J; Lindner HH
    Clin Chem; 2020 Sep; 66(9):1200-1209. PubMed ID: 32797158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.
    Foo JY; Wan Y; Schulz BL; Kostner K; Atherton J; Cooper-White J; Dimeski G; Punyadeera C
    Clin Chem; 2013 Oct; 59(10):1523-31. PubMed ID: 23820130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the Molecular Complexity of O-Glycosylated Endogenous (N-Terminal) pro-B-Type Natriuretic Peptide Forms in Blood Plasma of Patients with Severe Heart Failure.
    Halfinger B; Hammerer-Lercher A; Amplatz B; Sarg B; Kremser L; Lindner HH
    Clin Chem; 2017 Jan; 63(1):359-368. PubMed ID: 28062629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides.
    Ala-Kopsala M; Magga J; Peuhkurinen K; Leipälä J; Ruskoaho H; Leppäluoto J; Vuolteenaho O
    Clin Chem; 2004 Sep; 50(9):1576-88. PubMed ID: 15265819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure.
    Hammerer-Lercher A; Halfinger B; Sarg B; Mair J; Puschendorf B; Griesmacher A; Guzman NA; Lindner HH
    Clin Chem; 2008 May; 54(5):858-65. PubMed ID: 18339696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
    Semenov AG; Katrukha AG
    Clin Chem; 2016 Apr; 62(4):617-22. PubMed ID: 26864319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ProBNP That Is Not Glycosylated at Threonine 71 Is Decreased with Obesity in Patients with Heart Failure.
    Lewis LK; Raudsepp SD; Prickett TCR; Yandle TG; Doughty RN; Frampton CM; Pemberton CJ; Richards AM
    Clin Chem; 2019 Sep; 65(9):1115-1124. PubMed ID: 31092393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
    Suzuki S; Sugiyama S
    Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).
    Bhatt AS; Cooper LB; Ambrosy AP; Clare RM; Coles A; Joyce E; Krishnamoorthy A; Butler J; Felker GM; Ezekowitz JA; Armstrong PW; Hernandez AF; O'Connor CM; Mentz RJ
    J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29431103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemistry of B-type natriuretic peptide--where are we now?
    Mair J
    Clin Chem Lab Med; 2008; 46(11):1507-14. PubMed ID: 18842106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting Edge of Brain Natriuretic Peptide (BNP) Research - The Diversity of BNP Immunoreactivity and Its Clinical Relevance.
    Kuwahara K; Nakagawa Y; Nishikimi T
    Circ J; 2018 Sep; 82(10):2455-2461. PubMed ID: 30135320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
    Lam CS; Burnett JC; Costello-Boerrigter L; Rodeheffer RJ; Redfield MM
    J Am Coll Cardiol; 2007 Mar; 49(11):1193-202. PubMed ID: 17367664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches.
    Favresse J; Gruson D
    Ann Biol Clin (Paris); 2017 Jun; 75(3):259-267. PubMed ID: 28446390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the optimal cutoff values of plasma N-terminal pro-B-type natriuretic peptide levels for the diagnosis of heart failure in children of age up to 14 years.
    Lin CW; Zeng XL; Zhang JF; Meng XH
    J Card Fail; 2014 Mar; 20(3):168-73. PubMed ID: 24361777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department.
    Gaggin HK; Chen-Tournoux AA; Christenson RH; Doros G; Hollander JE; Levy PD; Nagurney JT; Nowak RM; Pang PS; Patel D; Peacock WF; Walters EL; Januzzi JL;
    Am Heart J; 2017 Oct; 192():26-37. PubMed ID: 28938961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
    Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
    Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.